Details of Disease

General Information of Disease (ID: DIS9YPUQ)

• Disease Name: Dermatological disease
• Disease Class: DA24: Oesophagitis
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS9YPUQ: Dermatological disease
• ICD Code: ICD-11: ICD-11: DA24.Y
• Disease Identifiers:
  MONDO ID: MONDO_0005093
  MESH ID: D012871
  UMLS CUI: C0037274
  MedGen ID: 20777
  SNOMED CT ID: 95320005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ammonium lactate	DMXMHBB	Approved	Small molecular drug	[1]
Betamethasone Valerate	DMMIAXO	Approved	Small molecular drug	[1]
Croconazole	DM1KL9T	Approved	Small molecular drug	[1]
Lanoconazole	DM1M4MT	Approved	Small molecular drug	[1]
Urea	DMUK75B	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LIAROZOLE	DM4OYXE	Phase 2/3	Small molecular drug	[3]
AM-001	DMGVQI8	Phase 2	NA	[4]
Pramiconazole	DMBH7XI	Phase 2	Small molecular drug	[5]
MK-51	DMS115I	Phase 1	Small molecular drug	[6]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Argidene	DM8RDYX	Discontinued in Preregistration	NA	[7]
GBL-100	DMB16IA	Discontinued in Phase 1	NA	[8]

This Disease is Treated as An Indication in 9 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AM-643	DMYB0DK	Investigative	Small molecular drug	[9]
CUV-9900	DMYHQV5	Investigative	NA	[9]
HO/02/10	DMSP9FK	Investigative	NA	[9]
HO/04/08	DMHASND	Investigative	NA	[9]
HYG-440	DM7XISZ	Investigative	NA	[10]
SIG-001	DMFMYFT	Investigative	NA	[9]
STD-06	DMBI36D	Investigative	NA	[9]
TDT-044	DMRU8WT	Investigative	NA	[11]
VN/13-1RA	DM4P1S5	Investigative	NA	[9]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4539).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5210).
• [4] ClinicalTrials.gov (NCT01938599) Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis. U.S. National Institutes of Health.
• [5] The efficacy of oral treatment with pramiconazole in pityriasis versicolor: a phase II a trial. Br J Dermatol. 2007 Jun;156(6):1385-8.
• [6] Clinical pipeline report, company report or official report of MIKA Pharma GmbH.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008220)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025789)
• [9] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [10] Clinical pipeline report, company report or official report of Hygeia Therapeutics.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).